August 2008 Volume 26 Number 8, pp 837 - 952
Visit Nature Biotechnology online to browse the journal.
Now available at http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0dXt0En
Please note that you need to be a subscriber to enjoy full text access to Nature Biotechnology online. To purchase a subscription, please visit:
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0aAP0El
Alternatively, to recommend a subscription to your library, please visit
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0BRQi0EJ
Bioentrepreneur: an online resource for budding business in the life sciences.
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0BkE0El
=====================================================================
=====================================================================
BIOPARTNERING
Visit our Biopartnering site to view Company Profiles and Partnership Opportunities:
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0BpT40Ex
=====================================================================
=====================================================================
FREE TRIAL AVAILABLE: SciBX: Science-Business eXchange
To keep up with the most important emerging science you could scan all of the top journals and hope you have enough time left to read the key papers ? or you can read SciBX every week.
SciBX - Identifying and distilling key papers, so you have time to read them.
To find out which papers made it into SciBX this week, sign up for a FREE TRIAL at http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0Burw0Ef
SciBX: Science-Business eXchange - new from the makers of Nature and BioCentury
=====================================================================
=====================================================================
BioBusiness Network 2008, 16th-18th September, President Wilson Hotel, Geneva
This is your only chance to meet the most senior representatives of your
partners of choice in an informal and intimate atmosphere. Don't waste time fighting through crowds to speak to decision makers, form valuable relationships over coffee or cocktails with AZ, GSK, BI, ROCHE, NOVARTIS, MERCK, WYETH, SHIRE, PFIZER, MERCK SERONO, LILLY and many more.
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2oS0Et
=====================================================================
----------------------
EDITORIAL
----------------------
Join the dots p837
Pushing biotech as the 'solution' to the world's problems is doing more harm than good.
doi:10.1038/nbt0808-837
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2oT0Eu
----------------------
NEWS
----------------------
EGFR inhibitors embrace KRAS pp839 - 840
Cormac Sheridan
doi:10.1038/nbt0808-839
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2oU0Ev
GSK slashes internal R&D p840
Nuala Moran
doi:10.1038/nbt0808-840
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2oV0Ew
Myriad stumbles, Wyeth closes on Alzheimer's pp841 - 843
Randy Osborne
doi:10.1038/nbt0808-841
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2oW0Ex
FDA and surrogate endpoints in Alzheimer's disease p843
Randy Osborne
doi:10.1038/nbt0808-843
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2oX0Ey
Infections cast cloud over Novartis' MS therapy pp844 - 845
Ken Garber
doi:10.1038/nbt0808-844
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2oY0Ez
India harmonizes regulations p845
K S Jayaraman
doi:10.1038/nbt0808-845a
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2oZ0E1
FDA probes TNF blockers p845
Brady Huggett
doi:10.1038/nbt0808-845b
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2oa0E8
GSK bird flu vaccine p846
Susan Aldridge
doi:10.1038/nbt0808-846a
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2ob0EA
Cabilly patent finale p846
Emily Waltz
doi:10.1038/nbt0808-846b
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2oc0EB
UK strong arms industry over drug pricing pp846 - 847
Peter Mitchell
doi:10.1038/nbt0808-846c
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2od0EC
Pharma to boycott UK? p847
Peter Mitchell
doi:10.1038/nbt0808-847a
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2oe0ED
EC/FDA joint inspections p847
Barbara Nasto
doi:10.1038/nbt0808-847b
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2of0EE
Supply size matters p847
Susan Aldridge
doi:10.1038/nbt0808-847c
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2og0EF
Profile: Olivier Rabin p849
With Beijing 2008 in full swing, the World Anti-Doping Agency's Olivier Rabin is looking for help from the biotech and pharma industry in the battle against cheaters.
Henry Nicholls
doi:10.1038/nbt0808-849
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2oh0EG
DATA PAGE
Q2 finance fall-off p850
Stacy Lawrence
doi:10.1038/nbt0808-850
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2oi0EH
NEWS FEATURE
Do biomaterials really mean business? pp851 - 853
Receiving only a fraction of the investment set aside for biofuels, biomaterials will likely have to piggyback on technological advances in energy production to compete with petroleum-based products in the marketplace. Emily Waltz reports.
Emily Waltz
doi:10.1038/nbt0808-851
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2oj0EI
----------------------
BIOENTREPRENEUR
----------------------
BUILDING A BUSINESS
The economics of licensing contracts pp855 - 857
Understanding why licensing works in biotech, and why deals are structured as they are, will help the entrepreneur negotiate.
Richard Mason, Nicos Savva and Stefan Scholtes
doi:10.1038/bioe.2008.7
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2ok0EJ
----------------------
OPINION AND COMMENT
----------------------
CORRESPONDENCE
GMO testing - trade, labeling or safety first? pp858 - 859
Arne Holst-Jensen
doi:10.1038/nbt0808-858
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2ol0EK
First evaluation of the European hESCreg pp859 - 860
Joeri Borstlap et al.
doi:10.1038/nbt0808-859
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2om0EL
Guidelines for reporting the use of mass spectrometry in proteomics pp860 - 861
Chris F Taylor et al.
doi:10.1038/nbt0808-860
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2on0EM
Guidelines for reporting the use of mass spectrometry informatics in proteomics p862
Pierre-Alain Binz et al.
doi:10.1038/nbt0808-862
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2oo0EN
Guidelines for reporting the use of gel electrophoresis in proteomics pp863 - 864
Frank Gibson et al.
doi:10.1038/nbt0808-863
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2op0EO
The PSI-MOD community standard for representation of protein modification data pp864 - 866
Luisa Montecchi-Palazzi et al.
doi:10.1038/nbt0808-864
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2oq0EP
----------------------
FEATURES
----------------------
Off-label or off-limits? pp867 - 875
Off-label prescribing is a fundamental fact of life of healthcare systems, but the promotion of off-label uses by drug sponsors is a fundamental sin. Regulators, legislators and drug makers are wrestling to find the right balance.
Mark Ratner and Trisha Gura
doi:10.1038/nbt0808-867
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2or0EQ
PATENTS
The London Agreement and the future of parallel imports pp877 - 879
Are European patents really getting cheaper, and if so, what effect will this have on parallel or so-called gray imports?
Justine Muir
doi:10.1038/nbt0808-877
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2os0ER
Recent patent applications in DNA synthesis p880
doi:10.1038/nbt0808-880
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2ot0ES
----------------------
NEWS AND VIEWS
----------------------
Sequencing sliced ends reveals microRNA targets pp881 - 882
Global sequencing of cleaved mRNAs enables identification of the targets of microRNA silencing.
Ian R Henderson and Steven E Jacobsen
doi:10.1038/nbt0808-881
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2ou0ET
Nematology: terra incognita no more pp882 - 884
The genome sequence of the plant-parasitic roundworm Meloidogyne incognita opens new avenues to boosting food production.
James P McCarter
doi:10.1038/nbt0808-882
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2ov0EU
Antibody-drug conjugates ace the tolerability test pp884 - 885
Near-uniform, low-level conjugation of cytotoxins to antitumor antibodies increases their tolerability without compromising efficacy.
Nitin K Damle
doi:10.1038/nbt0808-884
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2ow0EV
A welcome burst of human antibodies pp886 - 887
A new method allows rapid identification of human monoclonal antibodies from immune or vaccinated individuals.
Michael B Zwick, Johannes S Gach and Dennis R Burton
doi:10.1038/nbt0808-886
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2ox0EW
Research Highlights p888
doi:10.1038/nbt0808-888
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2oy0EX
----------------------
COMPUTATIONAL BIOLOGY
----------------------
COMMENTARY
Promoting coherent minimum reporting guidelines for biological and biomedical investigations: the MIBBI project pp889 - 896
Chris F Taylor et al.
doi:10.1038/nbt.1411
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2oz0EY
PRIMER
What is the expectation maximization algorithm? pp897 - 899
The expectation maximization algorithm arises in many computational biology applications that involve probabilistic models. What is it good for, and how does it work?
Chuong B Do and Serafim Batzoglou
doi:10.1038/nbt1406
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2o10EL
----------------------
RESEARCH
----------------------
PERSPECTIVE
Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment pp901 - 908
Jinhai Wang et al.
doi:10.1038/nbt.1484
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2o20EM
Article: http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2o30EN
ARTICLES
Genome sequence of the metazoan plant-parasitic nematode Meloidogyne incognita pp909 - 915
Biological control of the root-knot nematode Meloidogyne incognita, one of the world's most destructive crop pathogens, presents a major opportunity for safely improving global agricultural yields. Its 86-Mb genome - the first to be sequenced for a strictly parthenogenetic species - provides a blueprint to design new strategies for plant protection.
Pierre Abad et al.
doi:10.1038/nbt.1482
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2o40EO
Article: http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2o50EP
A drug-inducible transgenic system for direct reprogramming of multiple somatic cell types pp916 - 924
Generating induced pluripotent stem (iPS) cells is still an inefficient process, in part because the delivery of reprogramming factors by retroviral vectors yields cell populations that are genetically heterogeneous. Wernig et al. increase efficiency by producing iPS-cell chimeric mice from which they isolate cells bearing identical proviral insertions that support drug-inducible reprogramming.
Marius Wernig et al.
doi:10.1038/nbt1483
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2o60EQ
Article: http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2o70ER
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index pp925 - 932
Systemic toxicity associated with heterogeneity in the stoichiometries and sites of drug attachment is a major hurdle to developing antibody-drug conjugates (ADCs) for cancer therapy. Junutula et al. engineer cysteine residues in constant domains to produce near-homogenous ADCs that are better tolerated than conventional ADCs, without any loss of antitumor activity.
Jagath R Junutula et al.
doi:10.1038/nbt.1480
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2o80ES
Article: http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2pA0Ec
A small molecule enhances RNA interference and promotes microRNA processing pp933 - 940
Little is known about the regulation of RNA interference (RNAi). Shan et al. constructed a reporter system to monitor RNAi activity and identified a small molecule that increases RNAi by facilitating the interaction between small RNAs and a protein involved in small RNA loading and processing.
Ge Shan et al.
doi:10.1038/nbt.1481
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2pB0Ed
Article: http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2pC0Ee
LETTER
Global identification of microRNA-target RNA pairs by parallel analysis of RNA ends pp941 - 946
The targets of a microRNA (miRNA) are usually identified by computational analysis of sequences complementary to the miRNA. Working with inflorescence tissue of Arabidopsis, German et al. devise an experimental approach in which the products of miRNA-mediated cleavage are sequenced and used to identify miRNA-target RNA pairs.
Marcelo A German et al.
doi:10.1038/nbt1417
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2pD0Ef
Article: http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2pE0Eg
----------------------
ERRATA
----------------------
Erratum: HIV vaccine controversy p947
K S Jayaraman
doi:10.1038/nbt0808-947a
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2pF0Eh
Erratum: Response to HIV vaccine trials in India p947
K S Jayaraman
doi:10.1038/nbt0808-947b
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2pG0Ei
Erratum: Can 'double blockbuster' strengthen Amgen's backbone? p947
Cormac Sheridan
doi:10.1038/nbt0808-947c
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2pH0Ej
Erratum: Biotech slumps in Q1 p947
Stacy Lawrence
doi:10.1038/nbt0808-947d
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2pI0Ek
----------------------
NATUREJOBS
----------------------
CAREERS AND RECRUITMENT
Westernizing Eastern-bloc science pp949 - 950
Scientists in newer member countries are learning how to use what the European Union offers.
Quirin Schiermeier
doi:10.1038/nbt0808-949
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2pJ0El
PEOPLE
People p952
doi:10.1038/nbt0808-952
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0B2pK0Em
=====================================================================
Molecular Therapy focus on RNAi as a Therapeutic Strategy
www.nature.com/mt/webfocus/rnai
FREE access to various articles from the world's leading journals.
Presented by Molecular Therapy, this special web-focus gathers together top articles on RNAi originally published in Molecular Therapy, Nature, Nature Medicine, and British Journal of Cancer, and offers several of them to you FREE for a limited time!
Visit http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0Bu1U0E1 to access this special web focus today.
=====================================================================
You have been sent this Table of Contents Alert because you have opted in to
receive it. You can change or discontinue your e-mail alerts at any time,
by modifying your preferences on your nature.com account at:
http://ealerts.nature.com/cgi-bin24/DM/y/empP0Xztnp0HjC0Zzu0EE
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2008 Nature Publishing Group
=====================================================================
